Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Neoplasms 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 28Cisplatin 26Mitomycin 18BCG Vaccine 12pembrolizumab 9Paclitaxel 8Doxorubicin 7Docetaxel 75-aminolevulinic acid hexyl ester 7apaziquone 6Carboplatin 6vinflunine 5enfortumab vedotin 5atezolizumab 5Vinblastine 5Radiotherapy 5Methotrexate 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cystectomy 5durvalumab 4Surgical Procedures, Operative 4Nivolumab 4Transurethral Resection of Bladder 3Specimen Handling 3Selenium 3Radiation 3Filgrastim 3Cystoscopy 3BCG Connaught 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Urinary Bladder Neoplasms × Drug Delivery Systems × Clear all
NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05600322 2024-10-03

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Photocure

Phase 3 Completed
158 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡